Last reviewed · How we verify
Celebrex plus Metformin
This combination uses celecoxib (a COX-2 inhibitor) to reduce inflammation and metformin (a biguanide) to improve insulin sensitivity and glucose metabolism.
This combination uses celecoxib (a COX-2 inhibitor) to reduce inflammation and metformin (a biguanide) to improve insulin sensitivity and glucose metabolism. Used for Type 2 diabetes with inflammatory comorbidities (Phase 3 investigational).
At a glance
| Generic name | Celebrex plus Metformin |
|---|---|
| Sponsor | Guangxi Medical University |
| Drug class | COX-2 inhibitor + biguanide antidiabetic |
| Target | COX-2 and mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Rheumatology, Metabolic Disease |
| Phase | Phase 3 |
Mechanism of action
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin-mediated inflammation without affecting COX-1-dependent gastric protection. Metformin decreases hepatic glucose production and increases peripheral insulin sensitivity, lowering blood glucose levels. The combination may address both inflammatory and metabolic components of disease.
Approved indications
- Type 2 diabetes with inflammatory comorbidities (Phase 3 investigational)
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
- Lactic acidosis risk (metformin)
- Cardiovascular events (celecoxib)
Key clinical trials
- TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT (PHASE2)
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients (PHASE1, PHASE2)
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (PHASE2, PHASE3)
- Celebrex and Metformin for Postoperative Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celebrex plus Metformin CI brief — competitive landscape report
- Celebrex plus Metformin updates RSS · CI watch RSS
- Guangxi Medical University portfolio CI